| Literature DB >> 35481579 |
Catalina Ciocan1, Alessandro Godono2, Nicolò Franco3, Carlo La Vecchia4, Eva Negri5, Paolo Boffetta6, Enrico Pira7.
Abstract
OBJECTIVE: To update the analysis of mortality of a cohort of dyestuff workers, in Northern Italy, heavily exposed to carcinogenic aromatic amines.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35481579 PMCID: PMC9073764 DOI: 10.23749/mdl.v113i2.12893
Source DB: PubMed Journal: Med Lav ISSN: 0025-7818 Impact factor: 2.244
Exposure classification
| Group | Exposure |
|---|---|
| Group A | α-naphthylamine manufacture, β-naththylamine manufacture, benzidine manufacture, and mixed manufacture of benzidine and naphthylamine |
| Group B | workers never involved in the manufacture, but only in the use of naphthylamine and benzidine |
| Group C | workers with intermittent contact with naphthylamine and benzidine |
| Group D | workers who were involved only in the manufacture of fuchsin or o-toluidine |
| Group E* | workers employed in other jobs not involving exposure or unknown exposure |
* Excluded from the analysis
Numbers of observed and expected deaths from selected causes, 1946-2018
| Cause of death | Obs | Exp | SMR (95%CI) |
|---|---|---|---|
| All causes | 470 | 296.5 | 1.59 (1.45-1.74) |
| All cancers | 187 | 91.1 | 2.05 (1.77-2.37) |
| Oral and pharyngeal cancer | 7 | 2.8 | 2.46 (0.99-5.08) |
| Esophageal cancer | 5 | 2.2 | 2.23 (0.72-5.20) |
| Stomach cancer | 10 | 10.1 | 0.99 (0.47-1.82) |
| Colorectal cancer | 20 | 9.6 | 2.09 (1.28-3.23) |
| Liver cancer | 6 | 3.9 | 1.54 (0.56-3.35) |
| Pancreas cancer | 4 | 3.4 | 1.18 (0.32-3.02) |
| Peritoneal cancer | 2 | 0.4 | 4.60 (0.56-16.60) |
| Laryngeal cancer | 11 | 2.8 | 3.92 (1.95-7.01) |
| Lung cancer | 31 | 25.1 | 1.24 (0.84-1.86) |
| Pleural cancer | 4 | 0.8 | 5.29 (1.44-13.55) |
| Prostate cancer | 6 | 5.5 | 1.09 (0.40-2.37) |
| Bladder cancer | 60 | 4.0 | 14.86 (11.34-19.12) |
| Kidney cancer | 2 | 1.8 | 1.11 (0.13-3.40) |
| Brain & CNS cancers | 1 | 2.1 | 0.47 (0.01-2.60) |
| Lympho-hematopoietic neoplasms | 5 | 5.9 | 0.85 (0.28-1.98) |
| Lymphomas | 3 | 2.4 | 1.25 (0.26-3.66) |
| Myeloma | 0 | 1.0 | 0 (0-3.00) |
| Leukemias | 2 | 2.5 | 0.79 (0.10-2.84) |
| Ischemic heart diseases | 29 | 43.6 | 0.67 (0.45-0.96) |
| Cerebrovascular diseases | 31 | 32.5 | 0.95 (0.65-1.36) |
| Non neoplastic resp. dis. | 29 | 22.3 | 1.30 (0.87-1.87) |
| COPD | 20 | 13.2 | 1.52 (0.93-2.34) |
| Pneumoconiosis | 0 | 2.1 | 0 (0-1.43) |
| Liver cirrhosis | 43 | 11.6 | 3.70 (2.68-4.98) |
| External causes | 22 | 17.4 | 1.27 (0.79-1.92) |
CI, confidence interval; CNS, central nervous system; COPD, Chronic Obstructive Pulmonary Diseases; Exp, exp0ected deaths; ICD-IX, International Classification of Diseases, 9th version; Obs, observed deaths; SMR, standardized mortality ratio.
Mortality from bladder cancer, all other cancers, and all causes by time since last exposure, age at first exposure, and duration of exposure, 1946- 2018
| CATEGORY | BLADDER CANCER | ALL CAUSES | ||||
|---|---|---|---|---|---|---|
| Obs | Exp | SMR (95%CI) | Obs | Exp | SMR (95%CI) | |
| Time since last exposure | ||||||
| During exposure | 16 | 0.3 | 59.7 (34.1-97.0) | 57 | 38.3 | 1.5 (1.1-1.9) |
| 1-9 years | 15 | 0.5 | 29.3 (16.4-48.3) | 99 | 51.4 | 1.9 (1.6-2.3) |
| 10-19 years | 13 | 0.9 | 14.5 (7.7-24.9) | 101 | 68.4 | 1.5 (1.2-1.8) |
| 20-29 years | 11 | 0.9 | 12.0 (6.0-21.6) | 88 | 58.0 | 1.5 (1.2-1.9) |
| ≥ 30 years | 5 | 1.5 | 3.5 (1.1-8.0) | 125 | 80.4 | 1.6 (1.3-1.9) |
| p trend | <0.001 | 0.6 | ||||
| Age at first exposure | ||||||
| < 25 years | 19 | 1.1 | 17.3 (10.4-27.0) | 115 | 72.9 | 1.6 (1.3-1.9) |
| 25-34 years | 18 | 1.3 | 14.0 (8.3-22.1) | 135 | 85.6 | 1.6 (1.3-1.9) |
| ≥ 35 years | 23 | 1.7 | 14.0 (8.8-21.0) | 220 | 138.0 | 1.6 (1.4-1.8) |
| p-trend | 0.5 | 1.0 | ||||
| Duration of exposure | ||||||
| < 10 years | 16 | 2.1 | 7.6 (4.3-12.4) | 251 | 153.0 | 1.6 (1.4-1.9) |
| 10-19 years | 22 | 0.9 | 24.6 (15.4-37.3) | 120 | 72.5 | 1.7 (1.4-2.0) |
| ≥ 20 years | 22 | 1.0 | 21.1 (13.2-32.0) | 99 | 70.9 | 1.4 (1.1-1.7) |
| p-trend | 0.001 | 0.4 | ||||
CI, confidence interval; Exp, expected; Obs, observed; SMR, standardized mortality ratio.
Mortality from bladder cancer by job category, 1946- 2018
| JOB CATEGORY | Obs | Exp | SMR (95%CI) |
|---|---|---|---|
| Group A: Naphthylamine and benzidine manufacture | 35 | 0.8 | 45.4 (31.6-63.1) |
| Group B: Naphthylamine and benzidine use | 8 | 0.9 | 8.8 (3.8-17.3) |
| Group C: Intermittent contact with naphthylamine and benzidine | 11 | 2.0 | 5.5 (2.8-9.9) |
| Group D: Fuchsine or ơrtho-toluidine manufacture | 6 | 0.4 | 16.3 (6.0-35.5) |
CI, confidence interval; Exp, expected; Obs, observed; SMR, standardized mortality ratio.
Temporal parameters of the mesothelial tumor cases
| Case n. and tumor site | Years of employment in the dyestuff factory | Age at death | Latency period (years) |
|---|---|---|---|
| 1-pleura | 30 | 76 | 51 |
| 2-pleura | 6 | 83 | 64 |
| 3-pleura | 19 | 79 | 45 |
| 4-pleura | 1 | 69 | 33 |
| 5-peritoneum | 2 | 58 | 33 |
| 6-peritoneum | 6 | 56 | 36 |